AMENDMENTS TO THE CLAIMS

1. (Withdrawn) A compound of formula II,

Ar-C(O)-E-G-BN-L-A

formula II

wherein Ar is selected from the group consisting of an optionally substituted aryl ring, an optionally substituted aryl ring fused with one or more non-aromatic optionally substituted carbocylic rings, an optionally substituted aryl ring fused with one or more optionally substituted non-aromatic heterocyclic rings, an optionally substituted aryl ring fused with one or more optionally substituted aromatic or heteroaromatic rings,

C(O) is absent or a carbonyl carbon;

E is absent or selected from the group consisting of O and NH;

G is absent or selected from the group consisting of C_{1-6}-alkyl, C_{3-7}-cycloalkyl , C_{1-6}-alkyl-C_{3-7}-cycloalkyl, C_{3-7}-cycloalkyl-C_{1-6}-alkyl;

wherein BN is a basic nitrogen moiety selected from the group consisting of an amine group, an amide group, a carbamate or a carbamate derivative, urea or a urea derivative, a carbazimidamide, a nitrogen-containing heterocyclic, a nitrogen-containing heteroarylic ring, and an azabicyclic ring;

L is absent or selected from the group consisting of optionally substituted C_{1-10}-alkyl, optionally substituted C_{2-10}-alkenyl, optionally substituted C_{2-10}-alkynyl, C_{1-10}-alkylamine, C_{1-10}-alkoxy, C_{2-10}-alkenyloxy, C_{2-10}-alkynyloxy, C_{1-10}-alkoxycarbonyl, C_{2-10}-alkenyloxycarbonyl, C_{2-10}-alkynyloxycarbonyl; and

A is selected from the group consisting of $C(O)\text{-}OR^1$, $OP(O)OR^2OR^2$, $P(O)OR^2OR^2$, SO_2OR^2, SO_3H, OSO_3H, and PO_3H; wherein R^1 and R^2 are independently selected from the group consisting of H, M, C_{1-15}-alkyl, C_{3-8}-cycloalkyl, aryl, and $R^{1,2}$ wherein $R^{1,2}$ is R'-O-C(O)-R", R'-O-C(O)-O-R", R'-C(O)-O-R", wherein R' and R" are independently selected from the group consisting of C_{1-15}-alkyl, C_{3-8}-cycloalkyl and aryl.

2. (Withdrawn) The compound of claim 1, wherein the basic nitrogen moiety is selected from the group consisting of pyridyl (pyridinyl), pyrimidinyl, thiazolyl, pyrazolyl, imidazolyl, tetrazolyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydroquinolinyl,

tetrahydroisoquinolinyl, decahydroquinolinyl or octahydroisoquinolinyl, azocinyl, triazinyl, 6H-1,2,5-thiadiazinyl, 2H, 6H-1,5,2-dithiazinyl, phenoxathiinyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, 1H-indazolyl, purinyl, 4H-quinolizinyl, isoquinolinyl, quinolinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4a H-carbazole, carbazole, .beta.-carbolinyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl, phenazinyl, phenarsazinyl, phenothiazinyl, furazanyl, phenoxazinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidinyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl or oxazolidinyl. Preferable heterocyclic groups include piperidino, morpholino, thiamorpholino, pyrrolidino, pyrazolino, pyrazolidino, pyrazoryl, piperazinyl, thienyl, oxazolyl, tetrazolyl, thiazolyl, imidazolyl, imidazolinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, pyrrolidinyl and quinolyl, each of which may be optional substituted.

3. (Withdrawn) The compound of claim 1, wherein Ar is selected from substituted benzyl, naphthalene, indoline, indole, oxazinoindoline, indolizine, isoindoline, indene, indane, indazole, azulene, benzimidazole, benzofuran, benzothiophene, benzthiazole, purine, 4H-quinolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1.3-naphthyridine, pteridine, coumaran, benzodioxane, benzopyran, chroman, isochroman, carbazole, acridine, phenazine, phenothiazine, phenoxazine, thianthrene, phenanthrene, anthracene, tetraline, fluorene, and acenaphthylene, each of which may be optionally substituted.

4. (Withdrawn) The compound compound of claim 1, wherein L absent or selected from the group consisting of straight chain or branched optionally substituted C_{1-10}-alkyl, C_{1-10}-alkylamine, C_{1-10}-alkoxy, and C_{1-10}-alkoxycarbonyl.

5. (Withdrawn) The compound of claim 1, wherein A is selected from the group consisting of -C(O)-OR^1, and -P(O)OR^2OR^2, wherein R^1 and R^2 are independently selected from the group consisting of H, M, C_{1-15}-alkyl, C_{3-8}-cycloalkyl, and aryl.

6. (Withdrawn) The compound of claim 2, wherein the basic nitrogen moiety is selected from the group consisting of carbazimidamide and optional substituted piperidinyl.

7. (Withdrawn) The compound of claim 3, wherein Ar is selected from benzyl, naphthalene, indole, benzodioxane, indazole, and oxazinoindole.

8. (Withdrawn) The compound of claim 1, wherein G is absent or selected from the group consisting of C_{1-6}-alkyl, preferably absent or C_{1-3}-alkyl.

9. (Withdrawn) The compound of claim 1, wherein L is absent or selected from the group consisting of optionally substituted C_{1-8}-alkyl and wherein A is selected from the group consisting of -C(O)-OR^1, and -P(O)OR^2OR^2, wherein R^1 and R^2 are independently selected from the group consisting of H and C_{1-15}-alkyl.

10. (Withdrawn) The compound of claim 1, wherein G is absent or C_{1-3}-alkyl, the basic nitrogen moiety is selected from the group consisting of carbazimidamide and optional substituted piperidinyl and wherein L is absent or selected from the group consisting of optionally substituted C_{1-8}-alkyl.

11. (Withdrawn) The compound of claim 1 of the formula VI,



formula VI

wherein X and Y are independently selected from the group consisting of NH, O, C, and S;

L is absent or selected from the group consisting of straight chain or branched optionally substituted C_{1-10}-alkyl, optionally substituted C_{2-10}-alkenyl, optionally substituted C_{2-10}-alkynyl, C_{1-10}-alkylamine, C_{1-10}-alkoxy, C_{2-10}-alkenyloxy, C_{2-10}-alkynyloxy, C_{1-10}-alkoxycarbonyl, C_{2-10}-alkenyloxycarbonyl, C_{2-10}-alkynyloxycarbonyl;

A is selected from the group consisting of -C(O)-OR^1, -OP(O)OR^2OR^2, -P(O)OR^2OR^2, -SO_2OR^2, and PO_3H; wherein R^1 and R^2 are independently selected from the group consisting of H, M, C_{1-15}-alkyl, C_{3-8}-cycloalkyl, aryl, and $R^{1,2}$ wherein $R^{1,2}$ is R'-O-C(O)-R", R'-O-C(O)-O-R", R'-C(O)-O-R", wherein R' and R" are independently selected from the group consisting of C_{1-15}-alkyl, C_{3-8}-cycloalkyl and aryl;

and R^{16} and R^{13} are independently selected from the group consisting of H, OH, halogen, NH_2, O-C_{1-6}-alkyl, and C_{1-6}-alkyl.

12. (Currently amended) A compound represented by formula IV-P



formula IV-P

wherein L is absent or selected from the group consisting of straight chain or branched optionally substituted C_{1-10}-alkyl, optionally substituted C_{2-10}-alkenyl, optionally substituted C_{2-10}-alkynyl, C_{1-10}-alkylamine, C_{1-10}-alkoxy, C_{2-10}-alkenyloxy, C_{2-10}-alkynyloxy, C_{1-10}-alkoxycarbonyl, C_{2-10}-alkenyloxycarbonyl, C_{2-10}-alkynyloxycarbonyl; and

A is selected from the group consisting of $-C(O)-OR^1$, $-OP(O)OR^2OR^2$, $-P(O)OR^2OR^2$, $-SO_2OR^2$, and PO_3H; wherein R^1 and R^2 are independently selected from the group consisting of H, a counter-ion M, C_{1-15}-alkyl, C_{3-8}-cycloalkyl, aryl, and $R^{1,2}$ wherein $R^{1,2}$ is R'-O-C(O)-R", R'-O-C(O)-O-R", R'-C(O)-O-R", wherein R' and R" are independently selected from the group consisting of C_{1-15}-alkyl, C_{3-8}-cycloalkyl and aryl;

R^{13} is selected from the group consisting of H, halogen, NH_2, and C_{1-6}-alkyl; and

R^{16} is selected from the group consisting of H, halogen, OH, O-C_{1-6}-alkyl, and C_{1-6}-alkyl.

13. (Currently amended) A method of treating a cardiovascular disorder in an individual in need thereof, comprising ~~providing~~ administering a therapeutically effective amount of the compound of claim 12, or a pharmaceutically acceptable salt thereof, to said individual.

14. (Currently amended) A method of treating a gastrointestinal disorder in an individual in need thereof, comprising ~~providing~~ administering a therapeutically effective amount of the compound of claim 12, or a pharmaceutically acceptable salt thereof, to said individual.

15. (Withdrawn) The method of claim 13, wherein the cardiovascular disorder is selected from the group consisting of tachycardia, bradycardia, cardioexcitation, cardiodepression, arrhythmia, fibrillation, atrial fibrillation, Paroxysmal Supraventricular Tachycardia (PSVT), thromoembolisms and VTE.

16. (Previously presented) The method of claim 14, wherein the gastrointestinal disorder is selected from the group consisting of irritable bowel syndrome, gastrointestinal hypomotility disordersugastro-esophageal reflux, heartburn, mild oesophagitis, functional or nonulcer dyspensia, gastroparesis, nausea, vomiting, early satiety in the elderly, paraneoplastic of HIV-associated gastroparesis, drug-induced delays in gastric emptying, functional bowel obstructions, bowel obstructions caused by pancreatic cancer or drugs, and emesis.

17.-19. (Canceled).

20. (Currently amended) A method of treating a lower urinary tract disorder in an individual in need thereof comprising ~~providing~~ administering the compound of claim 12, or a pharmaceutically acceptable salt thereof, to said individual.

21. (Canceled)

22. (Previously presented) A pharmaceutical composition, comprising:

a compound according to claim 12; and

a pharmaceutically acceptable excipient.